- Real world data solutions in the post-marketing world: the multiple sclerosis experience
- Introduction to the MSBase international registry
- Methods for separating drug signals from bias in observational data
- Pharma / disease registry collaborations in comparative effectiveness analyses
- Big data: Big MS and beyond
This is the presenters’ personal opinion and does not necessarily represent true facts, the official views or policy of their organisation, nor the views of Evidence Life Science.